Overview

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase:

Phase 2

Details

Lead Sponsor:

Ocular Therapeutix, Inc.

Treatments:

Bimatoprost
Travoprost